Revisiting the association between human leukocyte antigen and end-stage renal disease

AbstractMultiple works have studied possible associations between human leukocyte antigen (HLA) alleles and end stage renal disease (ESRD) showing, however, contradictory and inconsistent results. Here, we revisit the association between ESRD and HLA antigens, comparing HLA polymorphism (at HLA-A, -B, -C, -DRB1, -DQB1 and DQA1 loci) in ESRD patients (n=497) and controls (n=672). Our data identified several HLA alleles that displayed a significant positive or negative association with ESRD. We also determined whether heterozygosity or homozygosity of the ESRD-associated HLA alleles at different loci could modify the prevalence of the disease. Few HLA allele combinations displayed significant associations with ESRD among which HLA-A*3–HLA-A*26 combination showed the highest strength of association (OR= 4.488, P≤ 0.05) with ESRD. Interestingly, the age of ESRD onset was not affected by HLA allele combinations at different loci. We also performed an extensive literature analysis to determine whether the association of HLA to ESRD can be similar across different ethnic groups. Our analysis showed at least for certain alleles, HLA-A*11, HLA-DRB1*11, and HLA-DRB1*4, a significant association of HLA to ESRD in different ethnic groups. The findings of our study will help in determining possible protective or susceptible roles of various HLA alleles in ESRD.

Download Full-text

Evaluation of Human Leukocyte Antigen Class I and Class II in End-Stage Renal Disease Occurrence in Indonesian Transplantation Patients

International Journal of Nephrology ◽

10.1155/2021/4219822 ◽

2021 ◽

Vol 2021 ◽

pp. 1-6

Author(s):

Hani Susianti ◽

Dwi Priyadi Djatmiko ◽

I Komang Adi Widana ◽

Deasy Ayuningtyas Tandio ◽

Catur Suci Sutrisnani ◽

...

Keyword(s):

Renal Disease ◽

Human Leukocyte Antigen ◽

End Stage Renal Disease ◽

Human Leukocyte ◽

Class I ◽

Leukocyte Antigen ◽

Hla Genes ◽

Stage Renal Disease ◽

End Stage ◽

Esrd Patients

Background. Genetic studies of end-stage renal disease (ESRD), including those of human leukocyte antigen (HLA) genes, have been reported in several populations but have not yet been evaluated in Indonesia. Some studies have reported that these genes had a substantial role in ESRD. This study aims to analyze the association between HLA genes and ESRD within the Indonesian community. Method. A retrospective study to investigate HLA class I and II alleles to find out the distribution of HLA-A, -B, -C, -DPB1, -DQB1, and -DRB1 in renal transplant recipients and to ascertain their role in susceptibility to ESRD was performed on totally 149 subjects, consisting of 69 ESRD patients and 80 healthy controls. HLA typing was determined using Luminex techniques. The allele and haplotype frequencies were compared between ESRD patients and controls. Result. High-frequency alleles were HLA-A ∗ 24 (43.6%), B ∗ 15 (38.2%), C ∗ 08 (30.8%), DRB1 ∗ 12 (47.3%), DQB1 ∗ 03 (50.6%), and DPB1 ∗ 13 (22.5%). HLA-A ∗ 24 p = 0.01 and HLA-B ∗ 35 p = 0.02 were associated with a protective effect, with OR 0.537 (95%CI 0.34–0.86) and 0.316 (95%CI 0.11–0.88), respectively. There were some two-locus haplotypes associated with susceptibility to ESRD, such as B ∗ 15-DRB1 ∗ 12, B ∗ 13-DRB1 ∗ 15, A ∗ 02-B ∗ 15, A ∗ 02-C ∗ 08, and B ∗ 13-DQB1 ∗ 05. HLA-A ∗ 02-B ∗ 15-DRB1 ∗ 12 and A ∗ 24-B ∗ 13-DRB1 ∗ 15 appear to be associated with susceptibility to ESRD. Conclusion. The allele groups of HLA-A ∗ 24 and HLA-B ∗ 35 are associated with protection from ESRD. Meanwhile, HLA-B ∗ 13-DRB1 ∗ 15 and A ∗ 24-B ∗ 13-DRB1 ∗ 15 are the most frequent HLAs associated with ESRD in two-locus and three-locus haplotype, respectively.

Download Full-text

Plasmapheresis Therapy in Kidney Transplant Rejection

Blood Purification ◽

10.1159/000493521 ◽

2018 ◽

Vol 47 (1-3) ◽

pp. 73-84 ◽

Cited By ~ 3

Author(s):

Pan Xie ◽

Min Tao ◽

Kanfu Peng ◽

Hongwen Zhao ◽

Keqin Zhang ◽

...

Keyword(s):

End Stage Renal Disease ◽

Multimodal Treatment ◽

Transplant Rejection ◽

Human Leukocyte ◽

Economic Costs ◽

Leukocyte Antigen ◽

Antibody Mediated Rejection ◽

Stage Renal Disease ◽

End Stage ◽

Optimal Treatment Strategy

Kidney transplantation (KT) is considered an optimal treatment strategy for end-stage renal disease. But human leukocyte antigen-sensitized, ABO-incompatible and antibody-mediated rejection might be the alarming hurdles in KT. Therapeutic plasma exchange is the mainstay of the antibody reduction therapy for reducing autoantibody more effectively. Even in the treatment for highly sensitized patients, it has played an indispensable role. However, clinicians should tailor therapies to individual patient’s needs and multimodal treatment will bring better outcomes. Early diagnosis and precise treatment would reduce morbidity, mortality, and economic costs.

Download Full-text

A path to renal transplantation in Nepal

Journal of Pathology of Nepal ◽

10.3126/jpn.v1i1.4453 ◽

1970 ◽

Vol 1 (1) ◽

pp. 52-55

Author(s):

J Enns ◽

G Aryal

Keyword(s):

Renal Transplantation ◽

Renal Replacement Therapy ◽

Human Leukocyte Antigen ◽

Replacement Therapy ◽

Human Leukocyte ◽

Cost Effective ◽

Leukocyte Antigen ◽

Post Transplant ◽

Stage Renal Disease ◽

End Stage

End Stage Renal Disease affects many people in the world. There are three methods of renal replacement therapy available to patients: Continuous ambulatory peritoneal dialysis, haemodialysis and transplantation. Transplantation is the most viable and cost effective form of renal replacement therapy that is available for these patients. There are 3 factors required to help ensure a successful renal transplantation program: A well legislated donor and recipient program, Human Leukocyte Antigen testing (pre and post transplant), as well as a post transplant follow up program. Keywords: Renal Transplant; South Asia; Nepal; Human Leukocyte Antigen DOI: 10.3126/jpn.v1i1.4453 Journal of Pathology of Nepal (2011) Vol.1, 52-55

Download Full-text

Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease

Transplantation Journal ◽

10.1097/tp.0000000000002669 ◽

2019 ◽

Vol 103 (11) ◽

pp. 2366-2372 ◽

Cited By ~ 5

Author(s):

Thomas R. Spitzer ◽

Nina Tolkoff-Rubin ◽

A. Benedict Cosimi ◽

Steven McAfee ◽

Bimalangshu R. Dey ◽

...

Keyword(s):

Multiple Myeloma ◽

Bone Marrow ◽

Renal Disease ◽

End Stage Renal Disease ◽

Leukocyte Antigen ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Association between Human Leukocyte Antigens (HLA-A, -B, and -DR) and end-stage renal disease in Kuwaiti patients awaiting transplantation

Renal Failure ◽

10.3109/0886022x.2014.937672 ◽

2014 ◽

Vol 36 (8) ◽

pp. 1317-1321 ◽

Cited By ~ 7

Author(s):

Youssef M. Mosaad ◽

Merveet Mansour ◽

Ibrahim Al-Muzairai ◽

Turky Al-Otabi ◽

Mohamed Abdul-Moneam ◽

...

Keyword(s):

Renal Disease ◽

End Stage Renal Disease ◽

Human Leukocyte ◽

Human Leukocyte Antigens ◽

Leukocyte Antigens ◽

Stage Renal Disease ◽

End Stage

Download Full-text

IgA Nephropathy Recurrence after Kidney Transplantation: Role of Recipient Age and Human Leukocyte Antigen-B Mismatch

American Journal of Nephrology ◽

10.1159/000506853 ◽

2020 ◽

Vol 51 (5) ◽

pp. 357-365

Author(s):

Lida M. Rodas ◽

Estibaliz Ruiz-Ortiz ◽

Adriana Garcia-Herrera ◽

Arturo Pereira ◽

Miquel Blasco ◽

...

Keyword(s):

Human Leukocyte Antigen ◽

Iga Nephropathy ◽

Protective Factor ◽

Human Leukocyte ◽

Clinical Indication ◽

Renal Outcome ◽

Leukocyte Antigen ◽

Risk Of Progression ◽

Stage Renal Disease ◽

End Stage

Background: Recurrence of immunoglobulin (Ig)A nephropathy (rIgAN) is a growing cause of kidney allograft dysfunction. This study was aimed at investigating factors associated with rIgAN and the subsequent progression to end-stage renal disease (ESRD). Methods: Retrospective study including consecutive patients with IgA nephropathy (IgAN) who received a kidney transplant in our center between 1992 and 2016 and had a renal biopsy by clinical indication. The date of detection of chronic kidney disease (CKD) 5 was used as renal outcome. Results: Eighty-six kidney transplants were performed in patients with IgAN, 38 (44%) were from living donors (related n = 26). rIgAN was diagnosed in 23 allografts (27%). Renal function and proteinuria at the end of the follow-up period were worst in the rIgAN patients compared to those without rIgAN (2.2 vs. 1.4 mg/dL, p = 0.014, and 1.16 vs. 0.49 g/day, p = 0.005, respectively). Risk of rIgAN and progression to CKD 5 decreased with patient’s age (hazard ratio [HR] 0.95, 95% CI 0.92–0.98, p = 0.002, and HR 0.97, 95% CI 0.83–0.97, p = 0.008 per year, respectively). Patients with rIgAN had a higher risk of progression to CKD 5 (HR 6.7, 95% CI 1.3–35.7, p = 0.025). Full donor-recipient mismatch in the human leukocyte antigen (HLA)-B loci decreased the risk of rIgAN (HR 0.22, 95% CI 0.06–0.76, p = 0.017). Conclusions: rIgAN was an independent risk factor for ESRD after renal allograft. Younger age increased the risk of rIgAN and CKD 5. Conversely, HLA-B mismatching was a potential protective factor for rIgAN of this glomerular disease.

Download Full-text